Status:
COMPLETED
Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis
Lead Sponsor:
VA Office of Research and Development
Conditions:
Alveolitis, Fibrosing
Fibrosis, Pulmonary
Eligibility:
All Genders
40-85 years
Phase:
PHASE2
Brief Summary
Medicines that decrease blood pressure in the lungs may help idiopathic pulmonary fibrosis (IPF) patients function better. This study will test whether sildenafil improves the ability to exercise in p...
Detailed Description
Idiopathic pulmonary fibrosis (IPF) is recognized as a predominantly noninflammatory paradigm of lung fibrosis, characterized by heterogeneous myofibroblast proliferation (usual interstitial pneumonia...
Eligibility Criteria
Inclusion
- Clinical diagnosis of IPF
- 40-85 years of age
- 6-minute walk distance 150-500 m
- FVC 40-90% predicted
- DLCO 30-90% predicted
Exclusion
- Severe pulmonary hypertension
- Severe heart failure
- FEV1/FVC \< 0.7
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT00359736
Start Date
July 1 2006
End Date
June 1 2009
Last Update
November 1 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Medical Center, Miami
Miami, Florida, United States, 33125